Perspective Therapeutics Inc. (AAJ0)
XFRA 
Summary
AAJ0 Chart
Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript
Perspective Therapeutics, Inc. ( CATX ) UBS Global Healthcare Conference 2025 November 11, 2025 4:15 PM EST Company Participants Joel Sendek - Chief Financial Officer Annie Cheng - Vice President of Investor Relations Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division Great. Thanks, everyone, for joining us.
Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy
Perspective Therapeutics' pipeline, led by VMT-a-NET, shows promising safety and early efficacy, but lacks clear superiority over existing therapies like Lutathera so far. The company maintains a strong cash position, supporting operations into late 2026, but the market now values CATX closer to its liquidity. Key risks include unproven clinical advantage for alpha emitter therapies and ongoing challenges with manufacturing, delivery, and market adoption.
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround
Perspective Therapeutics (CATX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Perspective Therapeutics Inc. (AAJ0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Perspective Therapeutics Inc. ever had a stock split?
Perspective Therapeutics Inc. Profile
| Health Care Technology Industry | Healthcare Sector | Johan M. Spoor CEO | XFRA Exchange | US46489V3024 ISIN |
| US Country | 138 Employees | - Last Dividend | 17 Jun 2024 Last Split | - IPO Date |
Overview
Perspective Therapeutics, Inc., operating alongside its subsidiaries, is at the forefront of developing precision-targeted alpha therapies (TAT) dedicated to the oncology field, with a focus on treating cancer patients suffering from various tumor types, including metastatic disease. The company engages in the discovery, design, and development of its pioneering program candidates, striving to offer new therapeutic possibilities for cancer patients. Formerly known as Isoray, Inc., Perspective Therapeutics changed its name in February 2022, marking a new era in its journey since its inception in 1998. Based in Seattle, Washington, Perspective Therapeutics has established itself as a notable entity in the biotechnology sector, particularly in delivering innovative cancer treatment solutions.
Products and Services
- VMT-a-NET
Currently in Phase 1/2a clinical trials, VMT-a-NET represents Perspective Therapeutics’ commitment to advancing cancer treatment. This program is targeting patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors. Specifically, it caters to those patients who have not previously received peptide-targeted radiopharmaceutical therapy, including alternatives like Lutathera, a beta-emitting therapy. VMT-a-NET stands out as a pivotal development in targeting specific cancer types with precision.
- VMT01
VMT01 is in the spotlight for its Phase 1/2a clinical trials targeting the second-line or later treatment of patients with metastatic melanoma, emphasizing those with progressive melanocortin 1 receptor (MC1R) positive tumors. This innovative approach highlights Perspective Therapeutics' efforts in expanding the range of effective treatments for different cancer types, especially for conditions that have limited treatment options.
In its pursuit of excellence in oncology, Perspective Therapeutics has forged a significant clinical trial collaboration with Bristol Myers Squibb. This partnership focuses on evaluating the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. Such collaborations underscore Perspective Therapeutics’ role in the broader ecosystem of cancer research, aiding in the development of groundbreaking therapies.
Contact Information
